Task Order D-13 PRE-CLINICAL MICROBIOLOGICAL, SAFETY, TOXICOLOGY, AND PHARMACOKINETIC SERVICES

任务令 D-13 临床前微生物学、安全性、毒理学和药代动力学服务

• 批准号: 10895064
• 负责人: JON MIRSALIS
• 金额: $ 227.2万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-11-01 至 2023-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10895064
• 关键词: Antimicrobial Resistance; Biological; Chemistry; Clostridium difficile; Communicable Diseases; Development; Development Plans; Drug Kinetics; Evaluation; In Vitro; Interventional Agent Development; Lead; Pseudomonas aeruginosa; Safety; Services; Staphylococcus aureus; Therapeutic; Toxicology; Toxin; in vivo; manufacture; pathogen; pre-clinical; product development; programs; therapeutic development

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins, including biodefense pathogens. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.

传染病干预药物开发的非临床服务计划提供服务，以促进针对引起传染病的病原体和/或毒素（包括生物防御病原体）的有前途的疗法的临床前产品开发。服务包括：临床前产品开发规划和评估；先导化合物的识别和开发；化学和 GMP 制造；体外和体内临床前微生物学、安全性、毒理学和药代动力学。